Sorry, you need to enable JavaScript to visit this website.
주요 콘텐츠로 건너뛰기

우리의 관리

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

CAREERS

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

이사회

Dr. Anand Tharmaratnam

Dr. Anand Tharmaratnam

Chairman
Dr. Anand Tharmaratnam

Dr. Anand Tharmaratnam

Chairman

Anand brings over 20 years of experience in global drug development and the CRO industry. He was previously the president of Asia Pacific at IQVIA. Anand is a medical doctor by training and graduated from the University College London, UK and trained in the anaesthesia.

Mr. Joel Thickins

Mr. Joel Thickins

Board Member
Mr. Joel Thickins

Mr. Joel Thickins

Board Member

Joel is a Partner at TPG Capital and leads the firm’s investment program in the ANZ region as Head of Australia and New Zealand. Joel has previously served on the board of Inghams Group Limited and Accolade Wines Holding Australia Pty Limited.

Before joining TPG, Joel was a director at CPE Capital (formerly known as CHAMP Private Equity) where he was responsible for the company’s activities in the industrial, agricultural services and consumer markets.

Dr. Fred Cohen

Dr. Fred Cohen

이사
Dr. Fred Cohen

Dr. Fred Cohen

이사

Fred Cohen은 TPG의 선임 고문이며 TPG Biotech 의 공동 창립자 겸 파트너였습니다. Fred는 Biocryst(BCRX) 및 CareDx(CDNA) 등 여러 생명공학 및 제약회사에서 이사직을 역임했으며 현재는 비영리 자폐증 지원 조직인 Sweetwater Spectrum의 공동 설립자입니다.

Mr. Vincent Wong

Mr. Vincent Wong

Board Member
Mr. Vincent Wong

Mr. Vincent Wong

Board Member

Vincent Wong is a Managing Director with TPG Capital and is based in Melbourne, where he works in TPG’s Australian team. Prior to joining TPG in 2011, Vincent served in the corporate advisory division at Goldman Sachs Australia. Vincent graduated from the University of Melbourne with BCommerce and BLaws (Honors).

Ms. Cai Li (蔡俐)

Ms. Cai Li (蔡俐)

Board Member
Ms. Cai Li (蔡俐)

Ms. Cai Li (蔡俐)

Board Member

Lydia Cai is a Managing Director with TPG Capital based in Beijing and leads TPG’s healthcare investments in the Greater China area. Prior to joining TPG in 2011, Lydia was an investment associate at HAO Capital, a China-focused early stage private equity fund focusing on growth-stage healthcare investments.

Dr. John Moller

Dr. John Moller

최고 경영자
Dr. John Moller

Dr. John Moller

최고 경영자

John은 2014년 1월 노보텍에 합류하여 노보텍의 아시아 운영 부문을 이끌고 있습니다. 노보텍에 입사하기 전 John은 IVF Australia 및 Queensland Fertility Group에서 상무이사직을 역임했으며 모회사인 Virtus Health의 이사였습니다. John은 의학박사입니다.

경영진

Dr. John Moller

Dr. John Moller

최고 경영자
Dr. John Moller

Dr. John Moller

최고 경영자

John은 2014년 1월 노보텍에 합류하여 노보텍의 아시아 운영 부문을 이끌고 있습니다. 노보텍에 입사하기 전 John은 IVF Australia 및 Queensland Fertility Group에서 상무이사직을 역임했으며 모회사인 Virtus Health의 이사였습니다. John은 의학박사입니다.

Michael stibilj

Michael stibilj

Chief Operating Officer
Michael stibilj

Michael stibilj

Chief Operating Officer

Michael has 25 years of experience in the CRO Industry. Prior to joining Novotech in 2017, Michael spent 15 years building and leading operations across Asia for Quintiles/IQVIA, and was senior advisor for TPG Capital.

Zidong Zhang

Zidong Zhang

Group Chief Finance Officer
Zidong Zhang

Zidong Zhang

Group Chief Finance Officer

Zidong Zhang is responsible for all aspects of financial management to support the growth of Novotech across Asia. Prior to joining Novotech, Dr. Zhang was CFO at Shanghai Henlius Biotech, Inc. a Hong Kong-listed global biopharmaceutical company based in Shanghai, where he built and managed the finance team and played an integral role in the company’s initial public offering in 2019. Prior to that, Dr. Zhang was an equity research analyst at UBS in New York, where he covered the United States large cap pharmaceutical and specialty pharmaceutical sector.

Barry Murphy

Barry Murphy

사업 개발 책임자
Barry Murphy

Barry Murphy

사업 개발 책임자

Barry는 2014년 7월 입사하여 노보텍의 비즈니스 개발 팀을 이끌고 있습니다. Barry는 Trinity College Dublin 졸업 후 약사로 시작했습니다. 그는 ICON에서 임상 연구 경력을 시작했으며 더블린과 시드니에서 근무하였습니다.

Andy Liu

Andy Liu

Head of China
Andy Liu

Andy Liu

Head of China

Andy worked at Covance, Inc., a global CRO, for more than 10 years in a number of executive positions. Most recently, he was General Manager of Covance's Central Laboratory Service, Asia Pacific, where he led a large multi-functional team of across multiple sites in APAC. Andy holds an MBA from the University of Chicago, an MS in Electrical Engineering from the Rose-Hulman Institute of Technology, and a BS in Electrical Engineering from Tsinghua University.

Veronica Holloway

Veronica Holloway

법률 책임자
Veronica Holloway

Veronica Holloway

법률 책임자

Veronica는 2014년 5월 노보텍에 입사하여 노보텍의 법률 부서를 구축했습니다. 노보텍에 합류하기 전, Veronica는 EY에서 선임 변호사, Clayton Utz에서 선임 사무 변호사 및 Novartis Pharmaceuticals Australia Pty Limited에서 법무 자문위원(파견직)으로 활동했습니다. Veronica는 BA/LLB/LLM을 취득했습니다.

Angela Edwardson

Angela Edwardson

인사 책임자
Angela Edwardson

Angela Edwardson

인사 책임자

Angela는 2015년11월에 노보텍에 입사하여 현재는인사운영 전략, 조직 개발, 보수 & 보상 및 직장 건강 및 안전 등을 담당하고 있습니다. Angela는 아시아 태평양 지역에서 선도적인 CRO 달성이라는 노보텍의 비전을 열정적으로 추구하고 있습니다.